{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"63"}],"units":"Participants"}],"groups":[{"description":"Patients receive ziv-aflibercept IV over 1 hour on day 1. Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity.\n\nziv-aflibercept: Given IV\n\nlaboratory biomarker analysis: Correlative studies\n\npharmacological study: Correlative studies","id":"OG000","title":"Treatment (Ziv-aflibercept)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Up to 3 years","title":"Objective Response Rate, Evaluated According to the RECIST Criteria","type":"PRIMARY","unitOfMeasure":"participants"}